FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322489441> ?p ?o ?g. }

• W4322489441 endingPage "3057" @default.
• W4322489441 startingPage "3049" @default.
• W4322489441 abstract "Abstract Long-term efficacy and safety of the extended half-life recombinant factor IX Fc fusion protein (rFIXFc) has been established among previously treated patients with severe hemophilia B in 2 phase 3 trials (B-LONG [#NCT01027364] and Kids B-LONG [#NCT01440946]) and a long-term extension study (B-YOND [#NCT01425723]). In this study, we report post hoc analyses of pooled longitudinal data for up to 6.5 years for rFIXFc prophylaxis. In the B-LONG study, subjects ≥12 years received weekly dose-adjusted prophylaxis (WP; starting dose, 50 IU/kg), individualized interval-adjusted prophylaxis (IP; initially, 100 IU/kg every 10 days), or on-demand dosing. In the Kids B-LONG study, subjects &lt;12 years received 50 to 60 IU/kg every 7 days, adjusted as needed. In the B-YOND study, subjects received WP (20-100 IU/kg every 7 days), IP (100 IU/kg every 8-16 days), modified prophylaxis, or on-demand dosing; switching between treatment groups was permitted. A total of 123 subjects from B-LONG and 30 from Kids B-LONG study were included, of whom 93 and 27, respectively, enrolled in the B-YOND study. The median cumulative duration of treatment was 3.63 years (range, 0.003-6.48 years) in B-LONG/B-YOND and 2.88 years (range, 0.30-4.80 years) in Kids B-LONG/B-YOND group. Annualized bleed rates (ABRs) remained low, annualized factor consumption remained stable, and adherence remained high throughout treatment. Low ABRs were also maintained in subjects with dosing intervals ≥14 days or with target joints at baseline. Complete resolution of evaluable target joints and no recurrence in 90.2% of baseline target joints during follow-up were observed. rFIXFc prophylaxis was associated with sustained clinical benefits, including long-term bleed prevention and target joint resolution, for severe hemophilia B." @default.
• W4322489441 created "2023-02-28" @default.
• W4322489441 creator A5005851218 @default.
• W4322489441 creator A5019518672 @default.
• W4322489441 creator A5026847169 @default.
• W4322489441 creator A5027136982 @default.
• W4322489441 creator A5028502237 @default.
• W4322489441 creator A5028799711 @default.
• W4322489441 creator A5030187450 @default.
• W4322489441 creator A5033744481 @default.
• W4322489441 creator A5038597185 @default.
• W4322489441 creator A5046729613 @default.
• W4322489441 creator A5058639047 @default.
• W4322489441 creator A5066731193 @default.
• W4322489441 creator A5071519850 @default.
• W4322489441 creator A5072045779 @default.
• W4322489441 creator A5072973093 @default.
• W4322489441 creator A5075720694 @default.
• W4322489441 creator A5079861916 @default.
• W4322489441 date "2023-06-30" @default.
• W4322489441 modified "2023-10-14" @default.
• W4322489441 title "Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B" @default.
• W4322489441 cites W1976624075 @default.
• W4322489441 cites W1997085090 @default.
• W4322489441 cites W2005719363 @default.
• W4322489441 cites W2007881102 @default.
• W4322489441 cites W2020123164 @default.
• W4322489441 cites W2315516779 @default.
• W4322489441 cites W2561075414 @default.
• W4322489441 cites W2584559805 @default.
• W4322489441 cites W2787721065 @default.
• W4322489441 cites W2792468493 @default.
• W4322489441 cites W2805945157 @default.
• W4322489441 cites W2902268034 @default.
• W4322489441 cites W2967535150 @default.
• W4322489441 cites W3029999028 @default.
• W4322489441 cites W3034174006 @default.
• W4322489441 cites W3047046471 @default.
• W4322489441 cites W3089829826 @default.
• W4322489441 cites W3111449782 @default.
• W4322489441 cites W3111847604 @default.
• W4322489441 cites W3113513514 @default.
• W4322489441 cites W3126150894 @default.
• W4322489441 cites W3151963925 @default.
• W4322489441 cites W3159829076 @default.
• W4322489441 cites W3174646334 @default.
• W4322489441 cites W3202924948 @default.
• W4322489441 cites W3207048560 @default.
• W4322489441 cites W3213148430 @default.
• W4322489441 doi "https://doi.org/10.1182/bloodadvances.2022009230" @default.
• W4322489441 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36848635" @default.
• W4322489441 hasPublicationYear "2023" @default.
• W4322489441 type Work @default.
• W4322489441 citedByCount "1" @default.
• W4322489441 countsByYear W43224894412023 @default.
• W4322489441 crossrefType "journal-article" @default.
• W4322489441 hasAuthorship W4322489441A5005851218 @default.
• W4322489441 hasAuthorship W4322489441A5019518672 @default.
• W4322489441 hasAuthorship W4322489441A5026847169 @default.
• W4322489441 hasAuthorship W4322489441A5027136982 @default.
• W4322489441 hasAuthorship W4322489441A5028502237 @default.
• W4322489441 hasAuthorship W4322489441A5028799711 @default.
• W4322489441 hasAuthorship W4322489441A5030187450 @default.
• W4322489441 hasAuthorship W4322489441A5033744481 @default.
• W4322489441 hasAuthorship W4322489441A5038597185 @default.
• W4322489441 hasAuthorship W4322489441A5046729613 @default.
• W4322489441 hasAuthorship W4322489441A5058639047 @default.
• W4322489441 hasAuthorship W4322489441A5066731193 @default.
• W4322489441 hasAuthorship W4322489441A5071519850 @default.
• W4322489441 hasAuthorship W4322489441A5072045779 @default.
• W4322489441 hasAuthorship W4322489441A5072973093 @default.
• W4322489441 hasAuthorship W4322489441A5075720694 @default.
• W4322489441 hasAuthorship W4322489441A5079861916 @default.
• W4322489441 hasBestOaLocation W43224894411 @default.
• W4322489441 hasConcept C126322002 @default.
• W4322489441 hasConcept C187212893 @default.
• W4322489441 hasConcept C2777081929 @default.
• W4322489441 hasConcept C2777232031 @default.
• W4322489441 hasConcept C2777288759 @default.
• W4322489441 hasConcept C2777785397 @default.
• W4322489441 hasConcept C2778385053 @default.
• W4322489441 hasConcept C2781221834 @default.
• W4322489441 hasConcept C67761136 @default.
• W4322489441 hasConcept C71924100 @default.
• W4322489441 hasConceptScore W4322489441C126322002 @default.
• W4322489441 hasConceptScore W4322489441C187212893 @default.
• W4322489441 hasConceptScore W4322489441C2777081929 @default.
• W4322489441 hasConceptScore W4322489441C2777232031 @default.
• W4322489441 hasConceptScore W4322489441C2777288759 @default.
• W4322489441 hasConceptScore W4322489441C2777785397 @default.
• W4322489441 hasConceptScore W4322489441C2778385053 @default.
• W4322489441 hasConceptScore W4322489441C2781221834 @default.
• W4322489441 hasConceptScore W4322489441C67761136 @default.
• W4322489441 hasConceptScore W4322489441C71924100 @default.
• W4322489441 hasIssue "13" @default.
• W4322489441 hasLocation W43224894411 @default.
• W4322489441 hasLocation W43224894412 @default.
• W4322489441 hasLocation W43224894413 @default.

• next